Living With Antipsychotic Injections: Safety and Family Support

This final part of the NP FADY series on long-acting antipsychotic injections covers real life with an LAI: the injection visit, side effects worth reporting, late or missed doses, health checks, costs and transportation, and how families can help without taking over.

What to know

• An injection still needs a plan for visits, health checks, side effects, and changes in symptoms. Ask who to call between visits, including evenings and weekends.
• Know the four movement problems that are easy to confuse: akathisia (inner restlessness), parkinsonism (stiffness and slowness), dystonia (sudden muscle spasms), and tardive dyskinesia (repeated unwanted movements).[1,2,13,20,21]
• Health checks continue. Weight, blood sugar, cholesterol, and other monitoring still apply because an injection does not remove the whole-body effects of the medicine.[3,4]
• Late or missed injections need a product-specific plan. Do not guess; the right catch-up depends on the exact product and how late the dose is.[5,6]
• The last injection keeps working for a long time. For example, paliperidone release from Invega Hafyera is predicted to last longer than 18 months, which matters for switching, side effects, and pregnancy planning.[7]
• Family support works best with permission. Agree on what help is wanted and what information may be shared.[8,9]

Zoom

Overview

A long-acting antipsychotic injection can reduce the work of taking a daily antipsychotic pill. It still needs a plan for visits, health checks, side effects, and changes in symptoms. The most useful plan answers three questions: What are we trying to improve? What problems should I report? Who do I contact between visits?

This is Part 3 of the NP FADY series on long-acting antipsychotic injections. Part 1 explains how these medicines work and what the evidence shows. Part 2 compares products and their different starting requirements. Here, the focus is living with treatment. Specific instructions depend on your exact product, health history, and treatment plan.

Your first LAI appointment

Start with your goals. Better sleep, fewer frightening experiences, staying out of the hospital, returning to work, or having fewer medication tasks may matter in different ways. Write down what would make treatment worthwhile to you. Also name what you worry about, including needles, weight, sexual side effects, costs, or feeling less in control.

Bring a medication list that includes prescriptions, nonprescription products, vitamins, and supplements. Tell the prescriber about allergies and past medication problems. Include medicines you stopped recently. These details help the team assess interactions and choose a safe starting plan.[10]

The team may first check how you tolerate the medicine by mouth. This is different from taking pills after the first injection while the injection begins providing coverage. A successful pill trial is reassuring, but it cannot rule out every later reaction. For example, RISPERDAL CONSTA labeling describes rare severe allergic reactions after an injection in people who previously tolerated oral risperidone.[11]

Before starting, ask for a written calendar showing injections, any temporary pills, early follow-up, and tests. If you already take another antipsychotic, confirm exactly which medicine continues and which changes. Do not guess from the injection date. Different formulations have different starts.[12]

Confirm that the clinic and insurer have arranged the medication before the appointment. Ask who is responsible for ordering it and what happens if it does not arrive. A reminder system should fit your life: a calendar alert, a paper card, or a trusted person’s reminder with your permission.

At the injection visit

LAIs are administered by healthcare professionals.[13] The product determines whether the injection goes into muscle or under the skin and which body sites are allowed.[14] These are not medicines for home self-injection.[13]

Tell the staff about needle fear or a history of fainting. Ask how privacy will be protected and what position they recommend. You can request a clear explanation before the injection. Do not promise yourself a painless experience: pain and local reactions vary. UZEDY, an under-the-skin risperidone product, can cause itching or a lump. A lump does not by itself mean the treatment failed.[14]

Ask for the product name, injection date, next due date, and clinic contact details in writing. Keep this information somewhere you can find it during travel, an urgent care visit, or a change of clinic. A photo of your appointment card may be convenient if you are comfortable storing it on your phone.

Routine visits may also include a symptom review or measurements. The visit is a chance to mention something small before it becomes a larger problem. Less frequent injections do not remove the need for health monitoring.[13]

A special rule for Zyprexa Relprevv

Olanzapine pamoate, sold as ZYPREXA RELPREVV, has a special safety requirement. After every injection, a healthcare professional must continuously observe the patient for at least three hours in a certified setting with emergency response access. Enrollment in its restricted REMS program is required. REMS means an FDA-required safety program.[15,16]

Before discharge, staff must confirm that the patient is alert, oriented, and free of signs of post-injection delirium/sedation syndrome.[16] Someone must accompany the patient to their destination.[15,16] Do not drive or operate heavy machinery for the rest of that day. Severe sleepiness or confusion can occasionally begin after the observation period, so know how to get medical help.[16] Plan transportation and the full visit length before treatment.

Side effects deserve a conversation

An injection changes delivery. It does not erase the active drug’s side effects. Some people have few problems; others need a change. Keep the focus on what you experience rather than assuming a brand is automatically easy or difficult to tolerate.

Sleepiness, dizziness when standing, constipation, dry mouth, or trouble sleeping can affect daily life.[11,17] Report when the problem started and what it prevents you from doing. Until you know how your medicine affects alertness and coordination, follow its driving precautions.[18] Rise slowly if you feel dizzy, and discuss falls or near-falls.[11] Do not add a sleep aid or other remedy without checking whether it interacts.[10]

Changes in appetite, weight, blood sugar, or blood fats can develop with second-generation antipsychotics. Blood tests matter because a person may not feel an early change. If weight rises, ask for a plan rather than waiting for the next annual visit. Discussion may include food access, activity, sleep, medical treatment, and whether the current antipsychotic still offers the best balance. A side effect is information for treatment, not a personal failure.[13]

Risperidone and paliperidone can raise prolactin, a hormone involved in milk production and reproductive function.[5] Possible signs include missed periods, breast milk leakage, breast enlargement, reduced sexual function, or erection problems.[5,13] Sustained elevations associated with low sex hormones may affect bone health.[5] Tell the team about these changes rather than assuming they are part of your psychiatric condition. The clinician can decide whether a hormone test or treatment change is appropriate.[13]

Aripiprazole has a different concern: new, intense urges to gamble, shop, eat compulsively, or engage in sexual activity. A patient may not immediately see the behavior as unusual. Report new urges promptly, especially if they cause financial or relationship harm.[17] The prescriber also needs to consider whether a mood episode or another cause is contributing.[6]

Four movement problems that are easy to confuse

These problems need different assessments. Do not use one movement label for all of them.

Akathisia is a distressing need to move, sometimes with pacing or an inability to sit comfortably. It may feel like anxiety from inside the body.[1] It is a recognized antipsychotic side effect, including with aripiprazole LAIs.[13,17] If restlessness begins or intensifies after a medication change, contact the team promptly and describe the timing.[10]

Drug-induced parkinsonism can involve stiffness, shaking, or slowed movement. It is a medication-related movement problem and does not automatically mean you have Parkinson disease.[2,13] Report trouble walking, dressing, writing, or using your hands. Haloperidol labeling identifies parkinsonism among its common adverse reactions.[19]

Acute dystonia means sustained muscle spasms. The neck may twist, the eyes may pull upward, or the jaw or tongue may be affected. It can occur early in treatment. Throat tightness or difficulty breathing or swallowing requires emergency help. Other new painful spasms need prompt assessment.[19,20]

Tardive dyskinesia, or TD, can cause repeated, unwanted movements of the mouth, tongue, face, trunk, arms, or legs.[13,21] It may persist despite changing or stopping medication and can be irreversible. It can also occur after relatively short exposure, although cumulative exposure matters.[21] New movements deserve assessment rather than an instruction to simply wait.[10,13]

Treatment options exist for movement side effects, but the right response depends on the type. Avoid borrowing another person’s movement medicine or stopping your own treatment to test a theory.[10,13]

When to get help

Get emergency help now for trouble breathing, facial or throat swelling, a seizure, inability to wake normally, or a medical emergency such as chest pain with fainting.[18,22] High fever together with severe stiffness and confusion can signal neuroleptic malignant syndrome, a rare, potentially life-threatening reaction.[23,27] Do not wait for the next appointment. Call 911 when immediate emergency assistance is needed.[22]

Go to emergency care for an erection lasting more than four hours, especially if painful.[7] Also seek emergency care if severe thirst or frequent urination is accompanied by vomiting, marked weakness, breathing problems, or confusion. These can be signs of a serious blood-sugar complication.[18,24] Symptoms involving breathing, consciousness, or immediate physical danger belong in emergency care.[22]

Contact the treatment team promptly for severe restlessness, new involuntary movements, repeated falls, new compulsive urges, worsening hallucinations, or a major change in sleep or mood. Ask for same-day guidance when symptoms are significant. If the clinic cannot be reached and you cannot stay safe, use emergency or crisis care.[10,17,25,26]

Discuss at follow-up mild, stable problems such as manageable injection soreness or a small stable lump. Call earlier if the site becomes increasingly painful, red, hot, swollen, or develops drainage.[11] You do not have to wait for the next injection to report a side effect.[10]

For suicidal thoughts or a mental health crisis in the United States, call or text 988, or chat at 988lifeline.org. A life-threatening situation requires 911. These are different services for different needs.[22,25]

Make health checks part of the plan

Ask who will order tests and review the results. Psychiatric and primary care teams may share this work, but someone should clearly own each follow-up. Keep copies of results if care is spread across clinics.

Before treatment, discuss baseline weight and BMI, pulse and blood pressure, glucose or A1c, lipids, and a clinical movement check. Other tests depend on the medicine and history.[3]

The American Psychiatric Association’s 2020 schizophrenia guidance gives one useful framework. It suggests BMI checks at each visit for six months, then at least quarterly; glucose or A1c and lipid checks around four months after a new treatment and at least annually; and movement assessment at each visit. A structured movement tool, such as AIMS, is suggested at least every six months for higher-risk patients and every twelve months for others, plus whenever new movements appear.[3]

These are a guideline framework, not an identical calendar for every diagnosis or product. Pulse and blood pressure are rechecked as clinically indicated. Prolactin testing depends on symptoms and history. Heart testing depends on the medication and cardiac risk. Current haloperidol decanoate labeling specifically calls for an ECG and blood electrolytes before treatment and later when clinically indicated.[3,19]

Kidney or liver tests, blood counts, and other checks depend on the drug, medical history, and symptoms. For example, certain labels recommend closer blood-count monitoring for people with a history of low white blood cells. A blood test schedule for someone taking another medication, such as lithium, may have separate requirements. Ask for your own written monitoring plan.[10,27]

Interactions still matter with an injection

The medicine still travels through your body. Tell every prescriber and pharmacist your exact injection name and last dose date, especially before starting or stopping another drug. Do the same for alcohol, cannabis, stimulants, and supplements. Accurate information helps the team evaluate symptoms without blame.[10,25]

Some antidepressants or other medicines slow the enzymes that process aripiprazole or risperidone. Other medicines, including carbamazepine, can speed processing and reduce exposure. The dose response is product-specific. Drugs that add sedation, lower blood pressure, or affect heart rhythm may also create problems. Paliperidone has different interaction and kidney-clearance considerations, so one product’s rules should not be copied to another.[14,19,21,27]

Starting or stopping smoking can change olanzapine exposure. Tell the team; this does not mean everyone needs an automatic dose change.[16]

Late or missed injections and returning symptoms

If you miss an injection, contact the clinic promptly with the product name and last injection date. The restart plan depends on the product, time elapsed, and where you are in treatment. It may involve an extra visit, another injection, or temporary oral medication.[5,6,12] Do not double up, restart leftover pills, or assume the same grace period applies to every LAI.[5,6,12,14]

Before travel, call ahead about appointment timing and where treatment could be given. A new clinic may need records, insurance authorization, and time to obtain the exact product. Keep the contact number with your travel information. If a supply problem appears, involve the prescriber before medication coverage becomes uncertain.

Symptoms can return even when injections are on time. The team should review the whole picture: sleep, stress, substance use, medical problems, new medicines, the injection record, and the illness course. Continuing symptoms are not proof that you did something wrong. Persisting hallucinations or mood changes need assessment, not an automatic early injection or added pill.[10,25,26]

If schizophrenia remains difficult to treat despite appropriate medication trials, a different formulation alone may not solve the problem. The VA/DoD guideline recommends clozapine for treatment-resistant schizophrenia. Ask whether a treatment-resistance evaluation is needed rather than cycling indefinitely through injection schedules.[13]

Changing or stopping an antipsychotic injection

The next injection is a decision, but the previous injection cannot be removed from the body. Exposure can continue well beyond the usual dosing interval.[13] INVEGA HAFYERA labeling predicts drug release beyond eighteen months; that does not mean full symptom protection lasts that long.[7] Residual medicine can also affect a switch and how quickly side effects settle.[13]

A prescriber-led change considers remaining exposure, the new medicine, overlapping effects, and relapse monitoring. Feeling better is a reason to review the plan, not evidence that treatment is no longer needed. There is no universal treatment duration that fits every patient. Discuss the illness course, prior recurrence, benefits, burdens, and preferences at planned reviews.[10,26]

Before a change, agree on your early warning signs and whom to call. For some people, changes in sleep, suspiciousness, or hearing voices matter. In bipolar disorder, less need for sleep, rising energy, unusually fast speech, impulsive decisions, or worsening depression may signal recurrence. The tracker should reflect your own history and a clinician-agreed response.[25,26]

Pregnancy and other health situations that need individual review

Pregnancy and breastfeeding: Discuss plans before a long-lasting injection when possible. If pregnancy occurs, contact the psychiatric and pregnancy-care teams rather than abruptly changing treatment.[7,10] Both untreated illness and medication exposure carry considerations. Labels warn that third-trimester exposure can cause newborn movement or withdrawal symptoms.[27] LAI-specific pregnancy evidence is limited, and long residual exposure makes planning especially important.[7]

Breastfeeding decisions depend on the molecule and the infant. Aripiprazole may reduce milk supply; its label recommends watching the breastfed infant for dehydration and poor weight gain.[6] Other labels identify different infant monitoring needs.[19] No blanket reassurance applies to every LAI.

Children and older adults: Approval of an oral medicine for a child does not establish approval of its injection. Pediatric LAI safety evidence and labeling require separate review. Older adults may have greater sensitivity, fall risk, and medical complexity. Antipsychotics carry a boxed warning about increased death in older adults with dementia-related psychosis; these LAIs are not approved for that purpose.[10,27]

Kidney or liver conditions: The restrictions vary. INVEGA SUSTENNA is not recommended with moderate or severe kidney impairment and requires dose modification for milder impairment. UZEDY has special oral-titration and starting instructions for kidney or liver impairment. Do not assume the injection avoids an organ problem because it bypasses swallowing.[5,14]

Parkinson disease or dementia with Lewy bodies: Haloperidol decanoate is contraindicated. Risperidone labeling warns of increased sensitivity, including confusion, falls, movement symptoms, and features of neuroleptic malignant syndrome. These diagnoses should be raised explicitly before treatment.[14,19]

Diabetes, heart disease, fainting, seizures, swallowing problems, low blood counts, and substance use also deserve a focused review. Bring the history rather than trying to decide alone which warning applies.[18,21]

Paying for treatment and getting there

Ask about the whole visit cost: the medicine, administration, appointment, any observation, and transportation. A list price is not a prediction of what you will pay.

Ask your insurer whether the medicine will be paid under a medical benefit or pharmacy benefit, whether advance approval is needed, and whether a particular pharmacy must supply it. Medicare distinguishes Part B coverage for certain provider-administered drugs from Part D coverage; individual coverage and costs still need confirmation.[28,29]

Manufacturer assistance has rules. For example, UZEDY’s current savings offer is for eligible commercially insured patients, excludes government insurance, and has benefit limits. It is not an offer for everyone. Ask separately about any patient-assistance option that fits your insurance and financial situation.[30]

California’s Medi-Cal transportation resource describes rides for eligible members who lack another way to attend covered care. Managed-care members can ask their plan’s member services about arrangements. Specialized medical transportation has separate requirements. This does not establish coverage of any particular LAI.[31]

If coverage is denied, ask the clinic and plan what documentation or appeal is available. If a product is no longer supplied, request a transition plan. Indivior discontinued PERSERIS availability effective May 31, 2026, while noting possible remaining supplier inventory and no safety or efficacy reason for the decision. Your prescriber should guide any replacement.[32]

Family support that protects choice

Ask the person what help would be useful: a ride, a reminder, company at an appointment, or assistance noting side effects. Start with their goals. A suggested question is, “What has treatment made easier, and what feels harder?” Avoid turning every conversation into a medication check.

Decide together who may receive information and what may be shared. HHS explains that HIPAA generally permits relevant sharing when an adult patient has the opportunity and does not object; other laws may set stricter rules. A family relationship does not give automatic access to every detail. Families can still share concerns with a clinician, even when the clinician cannot disclose patient information back.[8,9]

Keep recovery broader than injections. Therapy, work or school support, family education, and substance-use care can address needs medication alone does not meet. Families also deserve support for their own stress. Help should make the person’s life more manageable while preserving privacy and preferences.[25]

Fifteen questions for the next appointment

1. What goal are we trying to reach, and how will we judge progress?

2. What is the exact product name and approved use for my diagnosis?

3. What did my past response to this medicine tell us?

4. Do I need a pill trial, temporary pills, or extra starting visits?

5. When is each injection due, and who will arrange the medication?

6. Which side effects should I watch for first?

7. Could weight, movement, sexual, or hormonal changes affect this choice?

8. Which health checks do I need, when, and who reviews the results?

9. What should I do if the injection site changes or hurts?

10. Whom do I call between visits, including evenings or weekends?

11. What is my plan if an appointment is late or I travel?

12. How would we change treatment if it does not help or causes problems?

13. What should we review before pregnancy or breastfeeding?

14. What will I pay for the medicine, visit, administration, and transport?

15. What role do I want my family to have, and what may be shared?

Family support checklist

Complete this with the patient’s agreement:

• Ask what kind of help the person actually wants.

• Agree on reminders, transportation, or appointment support.

• Confirm who may receive information and its limits.

• Describe changes calmly, with dates and examples.

• Share concerns without calling every disagreement a symptom.

• Know the agreed early warning signs and contact plan.

• Support work, school, relationships, and everyday goals.

• Arrange support for family stress when needed.

Families may provide concerns to the clinician even when the clinician cannot share private details back. Applicable laws and circumstances determine what can be disclosed.[8,9]

Frequently asked questions

Will the injection hurt or leave a lump?

Pain and local reactions depend on the product and person. Under-the-skin products can leave a lump. Ask what is expected and report increasing pain, redness, heat, swelling, or drainage.[14]

Can I drive or work afterward?

Follow your product’s precautions and your response to it. For RELPREVV, review the observation, accompaniment, and no-driving rules above before arranging the visit.[16,18]

How can family help without taking over?

Agree on specific support, such as rides or reminders, and what information may be shared. Families can pass on concerns to clinicians without being entitled to every detail of care.[8,9]

Can it affect weight, periods, sexual function, or restlessness?

Yes, depending on the molecule. These are legitimate treatment concerns. Tracking when they begin helps the team assess metabolic effects, prolactin changes, and movement symptoms.[13]

What if I travel or miss an appointment?

Contact the clinic before travel or promptly after a missed visit. Give the exact product and last dose date. Restart instructions differ; do not improvise with leftover pills.[10,12]

Can I switch back to pills or another injection?

Switching may be possible, but residual medication affects timing and safety. Ask for a written, prescriber-led plan with follow-up.[10,13]

How long will the last injection keep working?

The duration depends on the product and person. Detectable drug or continued release is not the same as reliable symptom protection. The next due date should still be treated as part of your agreed plan.[7,10,13]

What if symptoms continue despite every injection?

Request an assessment of the medicine, medical and substance-use factors, sleep, and diagnosis. Persisting symptoms may call for a broader treatment evaluation.[13,25,26]

What should I discuss before pregnancy or breastfeeding?

Discuss the exact formulation, remaining exposure, illness risks, infant monitoring, and feeding goals with both care teams.[6,13] Avoid a self-directed change.[10]

Before your next appointment, write down one goal, one concern, and your last injection date. Ask the team to turn those into a written plan for follow-up and contact between visits.

Related reading on NP FADY

• Long-Acting Antipsychotics: How They Work and Who They Help
• Antipsychotic Injections: Comparing Your Treatment Options
• Weltruza: A Monthly Olanzapine Shot, and Everything to Ask Before the First Dose
• Cobenfy for schizophrenia: benefits, side effects, and dosing
• Bipolar and schizophrenia medicines in pregnancy and breastfeeding
• Why two opposite medicines both target dopamine

Educational disclaimer

This article is for education. It does not diagnose any condition, choose a medication for anyone, or replace the judgment of the clinician who knows your history. Do not start, stop, or change any medication without your prescriber. If there is imminent danger, or you cannot keep yourself or someone else safe, call 911 or go to the nearest emergency department. In the United States, call or text 988, or chat at 988lifeline.org, for any mental-health crisis. For a suspected overdose or accidental ingestion, call Poison Help at 1-800-222-1222. Regulatory and numeric claims in this article were checked against current FDA labeling and primary studies on September 30, 2026. Labels, approvals, and availability change; confirm current status with your prescriber or pharmacist before acting on anything here.

References

1. Akathisia Drug-Induced MeSH D017109. US National Library of Medicine. Current vocabulary record accessed 2026-09-30; term introduced 1993. https://www.ncbi.nlm.nih.gov/mesh/68017109 Accessed 2026-09-30.
2. Parkinsonian Disorders MeSH D020734. US National Library of Medicine. Current vocabulary record accessed 2026-09-30; term introduced 2000. https://www.ncbi.nlm.nih.gov/mesh/68020734 Accessed 2026-09-30.
3. APA Practice Guideline for the Treatment of Patients With Schizophrenia Third Edition clinician pocket guide. American Psychiatric Association / Guideline Central. 2020 guideline; authorized pocket guide linked from APA page updated 2025-09-12. https://eguideline.guidelinecentral.com/i/1303678-treatment-of-patients-with-schizophrenia/6 Accessed 2026-09-30.
4. The A1C Test and Diabetes. National Institute of Diabetes and Digestive and Kidney Diseases. Last reviewed April 2018; current resource accessed September 30, 2026. https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test Accessed 2026-09-30.
5. INVEGA SUSTENNA prescribing information. Janssen/Johnson & Johnson; FDA labeling reproduced by DailyMed. PI revised 2025-01; instructions 2025-02. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554 Accessed 2026-09-30.
6. ABILIFY MAINTENA prescribing information and Medication Guide. Otsuka; FDA labeling reproduced by DailyMed. DailyMed label version March 24, 2026; Medication Guide revised 03/2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6 Accessed 2026-09-30.
7. INVEGA HAFYERA prescribing information. Janssen / DailyMed. 2025-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cd61892-d2cb-434d-83ed-5c1b2c4e7a0b Accessed 2026-09-30.
8. Is a health care provider permitted to discuss an adult patient’s mental health information with the patient’s parents or other family members. US HHS Office for Civil Rights. Last reviewed 2017-09-12. https://www.hhs.gov/hipaa/for-professionals/faq/health-care-provider-permitted-discuss-adult-patients-mental-health-information-patients.html Accessed 2026-09-30.
9. What options do family members of an adult patient with mental illness have if they are concerned about the patient’s mental health and the patient refuses to agree to let a health care provider share information with the family? US HHS Office for Civil Rights. Last reviewed 2017-09-12. https://www.hhs.gov/hipaa/for-professionals/faq/what-options-do-family-members-adult-patient-mental-illness-have-if-they-are-concerned-about.html Accessed 2026-09-30.
10. Mental Health Medications. National Institute of Mental Health. Last reviewed December 2023; accessed 2026-09-30. https://www.nimh.nih.gov/health/topics/mental-health-medications Accessed 2026-09-30.
11. RISPERDAL CONSTA Prescribing Information. Janssen / DailyMed. Revised 1/2025; DailyMed updated 2025-11-05. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb34ee82-d2c2-43b8-ba21-2825c0954691 Accessed 2026-09-30.
12. ARISTADA prescribing information. Alkermes / DailyMed. 2025-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17a8d11b-73b0-4833-a0b4-cf1ef85edefb Accessed 2026-09-30.
13. VA/DoD Clinical Practice Guideline for Management of First-Episode Psychosis and Schizophrenia. US Department of Veterans Affairs / Department of Defense. April 2023, Version 2.0. https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/scz/VA-DOD-CPG-Schizophrenia-CPG_Finalv231924.pdf Accessed 2026-09-30.
14. UZEDY prescribing information. Teva; FDA labeling reproduced by DailyMed. PI revised 2025-10. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=734eb776-4be0-4808-834b-0d8b0f9e021e Accessed 2026-09-30.
15. ZYPREXA RELPREVV Supplement Approval and REMS Requirements NDA022173 S39. US Food and Drug Administration. 2021-04-28; Reference ID 4786995. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/022173Orig1s039ltr.pdf Accessed 2026-09-30.
16. ZYPREXA RELPREVV prescribing information. H2-Pharma/Cheplapharm; FDA labeling reproduced by DailyMed. PI revised 2026-05; Medication Guide 2026-01. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11544cba-64a9-49cb-8d74-da228053b252 Accessed 2026-09-30.
17. FDA Drug Safety Communication FDA warns about new impulse-control problems associated with aripiprazole. US Food and Drug Administration. 2016-05-03; FDA-linked archive capture 2025-12-14, accessed 2026-09-30. https://web.archive.org/web/20251214114626/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-new-impulse-control-problems-associated-mental-health Accessed 2026-09-30.
18. Aripiprazole Injection. American Society of Health-System Pharmacists AHFS Patient Medication Information via MedlinePlus National Library of Medicine. Last revised May 15, 2025; accessed September 30, 2026. https://medlineplus.gov/druginfo/meds/a615048.html Accessed 2026-09-30.
19. Haloperidol Decanoate Injection prescribing information. Generic product labeling reproduced by DailyMed. PI revised 2026-04. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14f40303-9604-4a30-8e86-8abaeb177ce1 Accessed 2026-09-30.
20. Fluphenazine decanoate prescribing information. Hikma / DailyMed. 2025-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311 Accessed 2026-09-30.
21. ERZOFRI prescribing information. Luye Pharma / DailyMed. 2025-03 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492bf9dd-868e-421a-92db-8cca8973aac1 Accessed 2026-09-30.
22. Frequently Asked Questions About Calling 911. National 911 Program / 911.gov. Last updated 2023-03-08; accessed 2026-09-30. https://www.911.gov/calling-911/frequently-asked-questions/ Accessed 2026-09-30.
23. Neuroleptic Malignant Syndrome MeSH D009459. US National Library of Medicine. Current vocabulary record accessed 2026-09-30; term introduced 1986. https://www.ncbi.nlm.nih.gov/mesh/68009459 Accessed 2026-09-30.
24. Diabetic Ketoacidosis. Centers for Disease Control and Prevention. 2024-05-15. https://www.cdc.gov/diabetes/about/diabetic-ketoacidosis.html Accessed 2026-09-30.
25. Schizophrenia. National Institute of Mental Health. Current federal patient resource; accessed 2026-09-30. https://www.nimh.nih.gov/health/publications/schizophrenia Accessed 2026-09-30.
26. Bipolar Disorder. National Institute of Mental Health. Current page accessed 2026-09-30. https://www.nimh.nih.gov/health/publications/bipolar-disorder Accessed 2026-09-30.
27. ABILIFY ASIMTUFII prescribing information. Otsuka / DailyMed. 2025-03 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da4c07fd-1130-4341-bb44-63acfa4162be Accessed 2026-09-30.
28. Prescription drugs outpatient. Centers for Medicare and Medicaid Services / Medicare.gov. Undated current page accessed 2026-09-30. https://www.medicare.gov/coverage/prescription-drugs-outpatient Accessed 2026-09-30.
29. Your guide to health insurance basics. Teva Pharmaceuticals. April 2025; NPS-40691; accessed 2026-09-30. https://www.uzedy.com/globalassets/uzedy/general-health-insurance-brochure.pdf Accessed 2026-09-30.
30. UZEDY Savings and Resources. Teva Pharmaceuticals. Undated terms accessed 2026-09-30. https://www.uzedy.com/savings-and-resources Accessed 2026-09-30.
31. Transportation Services. California Department of Health Care Services. Undated current page accessed 2026-09-30. https://www.dhcs.ca.gov/services/medi-cal-resources/transportation-services/ Accessed 2026-09-30.
32. Discontinue availability for PERSERIS. Indivior. Effective May 31, 2026; notice undated. https://www.indivior.com/our-products/discontinue-availability-of-perseris.html Accessed 2026-09-30.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, or chat at 988lifeline.org, available 24/7, free and confidential. En español: marque 988 y oprima 2, o envíe AYUDA al 988. Deaf or hard of hearing: 988 videophone (ASL) or TTY 711 then 988. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.